20
Participants
Start Date
April 30, 2007
Primary Completion Date
December 31, 2009
Study Completion Date
December 31, 2009
Ranolazine
500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
Placebo
Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
AHSP, Los Angeles
Collaborators (1)
CV Therapeutics
INDUSTRY
Cedars-Sinai Medical Center
OTHER